Lupo Pharmaceutical has partnered with Hansoh Pharmaceutical to develop and commercialize its next-generation BTK inhibitor, LP-168, for non-cancer indications in China, enhancing both companies' capabilities in the autoimmune disease market.

Target Information

Guangzhou Lupo Pharmaceutical Co., Ltd. (referred to as "Lupo Pharmaceutical") is an innovative drug company focused on developing treatments for malignant tumors and autoimmune diseases. Established in June 2018 by Dr. Tan Fenlai and Dr. Chen Yi, the company has swiftly positioned itself within the pharmaceutical sector, concentrating on key targets such as Bruton's tyrosine kinase (BTK), Bcl-2, and Bcl-xL. Lupo Pharmaceutical boasts a pipeline of over ten projects, including its flagship compound, Rocbrutinib (LP-168), which has received approval for key registration studies from the National Medical Products Administration of China (NMPA).

LP-168, a next-generation BTK inhibitor, is currently undergoing multiple clinical studies within China, with its most advanced phase being a pivotal Phase II trial for oncology applications. The firm emphasizes a commitment to research and development, aiming to become a leading multinational pharmaceutical enterprise based in the Greater Bay Area by integrating research, production, and sales.

Industry Overview in China

The pharmaceutical industry in China has experienced significant growth in recent years, driven by increasing healthcare demands from an aging population and rising prevalence of chronic diseases. With the government's push for innovation and the implementation